NSE · BSE · Real-time
High-value corporate events — new orders, fund raises, capacity expansions, and earning calls — analysed by AI the moment they hit the exchange.
Biocon Limited has initiated the commercial launch of Yesafili, its interchangeable biosimilar to Eylea, in the United States. The launch addresses a multi-billion dollar market opportunity in ophthalmology, providing a new treatment option for millions of Americans suffering from vision-threatening conditions.
Real-time NSE & BSE event alerts, AI-summarized filings, and instant order-win signals — free for 15 days, no card required.
